FocalTherics (NASDAQ:FOCL – Get Free Report) Director David Horn bought 10,000 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the transaction, the director directly owned 10,000 shares in the company, valued at approximately $47,500. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.
FocalTherics Price Performance
FOCL stock opened at $4.76 on Monday. The stock’s 50 day simple moving average is $5.39. The stock has a market capitalization of $178.40 million, a PE ratio of -4.62 and a beta of -0.04. FocalTherics has a fifty-two week low of $1.30 and a fifty-two week high of $6.40. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34.
FocalTherics (NASDAQ:FOCL – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The business had revenue of $13.20 million during the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. As a group, sell-side analysts anticipate that FocalTherics will post -0.78 EPS for the current year.
Institutional Trading of FocalTherics
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on FOCL shares. Mizuho set a $15.00 price target on shares of FocalTherics and gave the stock an “outperform” rating in a research note on Friday, July 17th. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday. Piper Sandler reiterated a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of FocalTherics in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, FocalTherics presently has a consensus rating of “Hold” and a consensus price target of $7.75.
Read Our Latest Analysis on FocalTherics
FocalTherics Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.
Featured Articles
- Five stocks we like better than FocalTherics
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for FocalTherics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FocalTherics and related companies with MarketBeat.com's FREE daily email newsletter.
